News & Updates

Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.

The oral selective Janus kinase 1/2 inhibitor baricitinib, when added to standard of care (SoC), reduced the risk of mortality among adults hospitalized with COVID-19. However, the primary outcome of disease progression was not met in the baricitinib group, results of the phase III COV-BARRIER study showed.

Use of sodium glucose co-transporter 2 inhibitors (SGLT2is) either alone or in combination with dipeptidyl peptidase 4 inhibitors (DPP4is) reduces the risk of hospitalization from heart failure (HHF), a study has shown. In contrast, thiazolidinediones alone or in combination with DPP4is increases HHF risk, but glucose-lowering can help reduce HHF.

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Intramuscular administration of single-dose AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab), significantly reduced the risk of developing symptomatic COVID-19 in adults, according to the PROVENT* study presented at IDWeek 2021.

In patients with chronic plaque psoriasis, once-daily treatment with roflumilast improved severity and burden of itch compared with vehicle cream, according to results of the phase III DERMIS-1 and DERMIS-2 trials presented at EADV 2021.